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Background: Although patients with end-stage renal disease (ESRD) experience
excess mortality compared with the general population, the standardized mortality
ratio (SMR) for Korean patients on dialysis has not yet been investigated. In this study,
we evaluated the SMR among all Korean ESRD patients on maintenance dialysis in
2009 and 2010, and compared it according to age categories, sex, and dialysis modality.
Methods: We used data from all patients on maintenance dialysis between January 1,
2009 and December 31, 2010 in Korea using the database of the Korean Health
Insurance Review and Assessment Service, and the SMR was determined by calculat-
ing of the ratio between the number of actual deaths and expected deaths.
Results: A total of 45,568 patients in 2009 and 48,170 patients in 2010 were included
in the analysis. The overall age- and sex-adjusted SMR was 10.3 [95% conﬁdence
interval (CI), 10.0–10.6] in 2009 and 10.9 (95% CI, 10.7–11.2) in 2010. The SMR for
females was much higher than for males. The SMR gradually decreased with
increasing age groups. The overall SMR for maintenance hemodialysis patients was
lower than that of peritoneal dialysis patients.
Conclusion: The SMR among Korean ESRD patients is likely to be higher than in other
countries. Further evaluation is needed to attempt to improve the outcomes.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
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Dialysis therapy has been considered a standard option for
patients with end-stage renal disease (ESRD) unless kidney
transplantation is possible. Since the process of separating
solutes in vitro using semipermeable membranes was invented
and the word “dialysis” was coined [1], great advances haveshed by Elsevier. This is an open access article under the CC BY-NC-ND
Kidney Res Clin Pract 33 (2014) 89–9490been made in this technology. In Korea, the ﬁrst report of
14 ESRD patients was published in 1967, and it described the
short-term results of dialysis treatment [2]. The prevalence of
ESRD patients is increasing rapidly due to the expansion of the
elderly population and an increase in the incidence of diabetes,
and in 2010, 46,818 patients were known to be on mainte-
nance hemodialysis (HD) or peritoneal dialysis (PD) [3]. In
addition, there were 4,560,457,000 cases of HD, and
373,958,629,000 Korean Won were claimed for the reimburse-
ment of HD in 2010 [4].
In order to collect nationwide data on dialysis therapy, the
Korean Society of Nephrology (KSN) launched an ofﬁcial
registry program in 1985, and in the annual report of mortality
data, the overall 5-year survival rate of male patients under-
going dialysis was 65.3% and that of female patients was 68.0%
[3]. The registry, however, includes only approximately two-
thirds of the patients undergoing dialysis in Korea because not
all the dialysis centers participated in enrollment for the
registry [5]. The mortality rate for the whole ESRD population
therefore needs to be determined.
When designing an epidemiological study, the issue of
confounding needs to be considered as well as interaction. Age
and sex have always been treated as important confounding risk
factors in clinical studies. The methods of “standardization” are
an effective way to deal with major confounding factors whereby
a standard population is chosen. By comparing the speciﬁcity of
a study population to that of a standard population, the effect of
the particular distribution of the confounding variable, such as
age and sex, in the study population is negated [6].
In the present study, we investigated mortality rates among
all Korean ESRD patients on maintenance dialysis in 2009 and
2010. In addition, we compared mortality rates between
dialysis patients and the whole general population by calculat-
ing the standardized mortality ratio (SMR) according to age
categories, sex, and dialysis modality.Methods
Data source and study population
All data used in the present study were obtained from the
Korean Health Insurance Review and Assessment Service
(HIRA) database. In Korea, all citizens are obliged to join the
National Health Security System as a mandatory social insur-
ance program. In 2007, 96% of citizens were covered by the
National Health Insurance Scheme, which is ﬁnanced by
contributions from those insured and government subsidies,
and the remaining 4% of citizens were covered by a separate
program called Medical Aid, which is a public assistance
program that provides minimum livelihood assistance to
low-income households [7]. Under these programs, all claims
for dialysis-associated medical services submitted by health
care providers are reviewed by the HIRA [7,8]. Using the HIRA
database, we were able to identify every ESRD patient among
the entire South Korean population and analyze the data for all
ESRD patients on dialysis therapy.
For the analysis of the mortality rate among dialysis
patients, we initially identiﬁed all patients on maintenance
dialysis between January 1, 2009 and December 31, 2010 in
Korea. Patients who were younger than 20 years or who
survived fewer than 90 days from the date of dialysis initiation
were excluded.Patients who had started HD were identiﬁed by the
occurrence of a new claim for the payment code of HD:
O7020 or O7021; patients who had started PD were identiﬁed
by the simultaneous occurrence of new claims for the payment
code of PD: O7061, O7062, O7071, or O7072, and for the drug
code of PD solutions speciﬁed in the National Health Insurance
Claims Database. The death of a dialysis patient in 2009 and
2010, respectively, was deﬁned as a case in which the dis-
charge form in the claims data was classiﬁed as death or there
were no records of a hospital visit over 180 days, regardless of
the type of care center. The crude mortality rate was a measure
of the number of deaths divided by that of a population per
year. The number and mortality rate of the entire population in
2009 and 2010 were obtained from Statistics Korea [9].
Statistical analysis
All statistical analyses were performed using SAS version
9.3 (SAS Institute, Cary, NC, USA). To compute indirect stan-
dardization by a typical method, we implemented two-stage
processes in the following manner. First, in order to obtain the
expected number of deaths in dialysis patients, we multiplied
the mortality rate of the national population as a standard
population by the prevalence of dialysis patients. By default,
10-year-old age-sex-speciﬁc death rates in the standard popu-
lation were applied to the dialysis patients with the same unit
as a study population. Second, the SMR was determined
by calculating the ratio between the number of observed
deaths (e) and expected deaths (E). Let ei be the number of
events in the ith age group of a study population. The events
are deaths in this study. Let pi be the size of the ith age group
of the study population and the superscript o denote the
whole population. Here, rðoÞi ¼ eðoÞi =pðoÞi . is the event rate in the
ith age group for the whole population. The formula of the
SMR can be represented as follows [10,11]:
Ε¼∑rðoÞi pi ¼∑
eðoÞi
PðoÞi
 !
pi
SMR¼ Observed deaths
Expected deaths
¼ e
Ε
The 95% conﬁdence interval (CI) of the SMR was calculated
using the method presented by Vandenbroucke [12], and its
formula is deﬁned as follows:
Lower CI of SMR¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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Upper CI of SMR¼
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þ1 2
Expected deathsResults
Baseline characteristics
In total, 45,568 patients in 2009 and 48,170 patients in 2010
who received dialysis due to ESRD were included in this study
(Table 1). The mean age of prevalent patients on maintenance
dialysis was 57.8713.3 years in 2009 and 58.4713.4 years in
Table 1. Standardized mortality ratios among prevalent dialysis patients in 2009 and 2010.
Year Sex Age group (y)
Whole population Dialysis patients
N Observed
deaths
(%)n
Mortality
rate
(/100,000)
N Prevalence
(PMP)
Observed
deaths (%)n
Expected
deaths
Mortality
rate
(/100,000)
SMR (95% CI)
2009 Male 20–29 3,711,498 2,462 (0.1) 66.3 633 170.6 66 (10.4) 0.4 10,426.5 157.2 (120.9–200.9)
30–39 4,205,242 4,945 (0.1) 117.6 1,939 461.1 185 (9.5) 2.3 9,541.0 81.1 (69.6–94.0)
40–49 4,311,802 13,058 (0.3) 302.8 4,312 1,000.0 450 (10.4) 13.1 10,436.0 34.5 (31.3–37.9)
50–59 3,166,112 20,383 (0.6) 643.8 6,675 2,108.3 656 (9.8) 43.0 9,827.7 15.3 (14.1–16.5)
60–69 1,874,749 28,047 (1.5) 1,496.0 7,281 3,883.7 933 (12.8) 108.9 12,814.2 8.6 (8.0–9.1)
70–79 1,025,013 37,862 (3.7) 3,693.8 4,114 4,013.6 695 (16.9) 152.0 16,893.5 4.6 (4.2–4.9)
Z80 262,882 28,764 (10.9) 10,941.8 747 2,879.6 154 (20.6) 81.7 20,615.8 1.9 (1.6–2.2)
Subtotal 18,557,298 135,521 (0.7) 730.3 25,701 1,385.0 3,139 (12.2) 401.4 12,213.5 7.8 (7.5–8.1)
Female 20–29 3,435,250 1,589 (0.0) 46.3 412 119.9 50 (12.1) 0.2 12,135.9 262.4 (193.4–347.8)
30–39 4,006,927 2,813 (0.1) 70.2 1,394 347.9 127 (9.1) 1.0 9,110.5 129.8 (107.8–154.9)
40–49 4,159,745 4,912 (0.1) 118.1 3,257 783.0 351 (10.8) 3.8 10,776.8 91.3 (81.8–101.5)
50–59 3,169,853 6,999 (0.2) 220.8 4,937 1,557.5 535 (10.8) 10.9 10,836.5 49.1 (44.9–53.5)
60–69 2,094,210 12,086 (0.6) 577.1 5,437 2,596.2 807 (14.8) 31.4 14,842.7 25.7 (23.9–27.6)
70–79 1,489,171 28,666 (1.9) 1,925.0 3,691 2,478.6 754 (20.4) 71.1 20,428.1 10.6 (9.9–11.4)
Z80 623,820 50,590 (8.1) 8,109.7 739 1,184.6 196 (26.5) 59.9 26,522.3 3.3 (2.8–3.8)
Subtotal 18,978,976 107,655 (0.6) 567.2 19,867 1,046.8 2,820 (14.2) 178.3 14,194.4 15.8 (15.2–16.4)
Total 37,536,274 243,176 (0.6) 647.8 45,568 1,214.0 5,959 (13.1) 538.1 13,077.2 10.3 (10.0–10.6)
2010 Male 20–29 3,648,101 2,384 (0.1) 65.3 623 170.8 108 (17.3) 0.4 17,335.5 265.3 (216.7–321.5)
30–39 4,156,437 4,697 (0.1) 113.0 1,967 473.2 296 (15.0) 2.2 15,048.3 133.2 (118.1–149.6)
40–49 4,329,776 12,697 (0.3) 293.2 4,357 1,006.3 667 (15.3) 12.8 15,308.7 52.20 (48.2–56.4)
50–59 3,336,194 21,130 (0.6) 633.4 7,105 2,129.7 888 (12.5) 45.0 12,498.2 19.7 (18.4–21.1)
60–69 1,917,923 27,812 (1.5) 1,450.1 7,663 3,995.5 1,090 (14.2) 111.1 14,224.2 9.8 (9.2–10.4)
70–79 1,091,286 40,404 (3.7) 3,702.4 4,777 4,377.4 781 (16.3) 176.9 16,349.2 4.4 (4.1–4.7)
Z80 285,683 30,955 (10.8) 10,835.4 906 3,171.3 177 (19.5) 98.2 19,536.4 1.8 (1.5–2.1)
Subtotal 18,765,400 140,079 (0.7) 746.5 27,398 1,460.0 4,007 (14.6) 446.6 14,625.2 9.0 (8.7–9.3)
Female 20–29 3,353,397 1,376 (0.0) 41.0 422 125.8 70 (16.6) 0.2 16,587.7 404.3 (313.4–513.1)
30–39 3,971,864 2,576 (0.1) 64.9 1,381 347.7 208 (15.1) 0.9 15,061.6 232.2 (201.1–266.7)
40–49 4,177,450 4,882 (0.1) 116.9 3,238 775.1 399 (12.3) 3.8 12,322.4 105.4 (95.1–116.5)
50–59 3,340,123 7,174 (0.2) 214.8 5,121 1,533.2 566 (11.1) 11.0 11,052.5 51.5 (47.2–56.0)
60–69 2,130,602 11,956 (0.6) 561.2 5,577 2,617.6 846 (15.2) 31.3 15,169.4 27.0 (25.2–29.0)
70–79 1,554,048 29,124 (1.9) 1,874.1 4,132 2,658.9 756 (18.3) 77.4 18,296.2 9.8 (9.1–10.5)
Z80 674,929 54,546 (8.1) 8,081.7 901 1,335.0 194 (21.5) 72.7 21,531.6 2.7 (2.3–3.1)
Subtotal 19,202,413 111,634 (0.6) 581.4 20,772 1,081.7 3,039 (14.6) 197.4 14,630.3 15.4 (14.8–16.0)
Total 37,967,813 251,713 (0.7) 663.0 48,170 1,268.7 7,046 (14.6) 596.1 14,627.4 10.9 (10.7–11.2)
n The proportion of observed death (%) is the percentage of the number of observed deaths divided by the population.
CI, conﬁdence interval; PMP, per million population; SMR, standardized mortality ratio.
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Kidney Res Clin Pract 33 (2014) 89–94922010. The number of males was 25,701 (56.4%) in 2009 and
27,398 (56.9%) in 2010.
The patients were divided into seven age categories: 20–29
years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–
79 years, andZ80 years. In 2009 the number of patients
included in each group were 1,045 (2.3%), 3,333 (7.3%), 7,569
(16.6%), 11,612 (25.5%), 12,718 (27.9%), 7,805 (17.1%), and 1,486
(3.3%), respectively. In 2010 the number of patients included in
each group were 1,045 (2.2%), 3,348 (7.0%), 7,595 (15.8%),
12,226 (25.4%), 13,240 (27.5%), 8,909 (18.5%), and 1,807
(3.7%), respectively.
The prevalence of patients on dialysis therapy was 1,214.0
per million population (PMP) and 1,268.7 PMP in 2009 and
2010, respectively (Table 1). The prevalence of male patients
was higher than that of female patients (1,385.0 PMP vs.
1,046.8 PMP in 2009; 1,460.0 PMP vs. 1,081.7 PMP in 2010).
The prevalence among patientso50 years of age was much
lower compared with those aged Z50 years. The peak pre-
valence in males was in patients aged 70–79 years (4,013.6
PMP and 4,377.4 PMP in 2009 and 2010, respectively), whereas
the prevalence among female patients aged 70–79 years was
similar to among those aged 60–69 years in both years (Fig. 1).
The total numbers of HD and PD patients in 2009 were
36,285 (79.6%) and 9,283 (20.4%), respectively; whereas those
of HD and PD patients in 2010 were 38,750 (80.4%) and 9,420
(19.6%), respectively (Table 2). When we evaluated the age and
sex distribution of patients on maintenance dialysis, the
number of HD patients aged 60–69 years was the highest,
whereas the number of PD patients aged 50–59 years was the
highest in both male and female patients.
The SMR in Korean ESRD patients on maintenance dialysis in
2009 and 2010
When we calculated the crude mortality rates for 1 year,
5,959 patients (13.1%) in 2009 and 7,046 patients (14.6%) in
2010 died (Table 1). The mortality rate for females was higher
than that for males in 2009 [2,820 (14.2%) vs. 3,139 (12.2%)],
whereas the mortality rate for females in 2010 was similar to
that for males [3,039 (14.6%) vs. 4,007 (14.6%)]. Among HDFigure 1. Differences in the prevalence of dialysis patients according
to age categories and sex. The peak prevalence in males was in patients
aged 70–79 years, whereas the prevalence among female patients aged
70–79 years was similar to those aged 60–69 years in 2009 and 2010. In
addition, the prevalence among patients aged Z70 years in 2010 was
higher than in 2009. PMP, per million population.patients, 4,842 patients (13.3%) and 5,600 patients (14.5%) died
in 2009 and 2010, respectively, whereas the number of deaths
among PD patients was 1,117 (12.0%) and 1,446 (15.4%),
respectively (Table 2).
The overall age- and sex-adjusted SMR for all dialysis
patients was 10.3 (95% CI, 10.0–10.6) in 2009 and 10.9 (95%
CI, 10.7–11.2) in 2010 (Table 1). Because the mortality rate in
the overall population in Korea was lower in females than in
males, the SMR for females was much higher than that of
males: 15.8 (95% CI, 15.2–16.4) vs. 7.8 (95% CI, 7.5–8.1) in 2009
and 15.4 (95% CI, 14.8–16.0) vs. 9.0 (95% CI, 8.7–9.3) in 2010. In
2009, the SMR for males gradually decreased from 157.2 (95%
CI, 120.9–200.9) among patients between 20 years and 29
years of age to 1.9 (95% CI, 1.6–2.2) among patients agedZ80
years, and the SMR for females also decreased from 262.4 (95%
CI, 193.4–347.8) among patients aged 20–29 years to 3.3 (95%
CI, 2.8–3.8) among patients agedZ80 years. A similar decrease
in SMR with increasing age was observed in 2010.
The overall SMRs for HD patients were 9.7 (95% CI, 9.5–
10.0) and 10.0 (95% CI, 9.7–10.3) in 2009 and 2010, respec-
tively, and these were lower than that of PD patients: 13.6 (95%
CI, 12.8–14.4) in 2009 and 17.2 (95% CI, 16.3–18.2) in 2010
(Table 2). Among patients aged 30–39 years and 40–49 years,
however, the SMR for HD patients was higher compared with
PD patients, though the SMR was comparable between HD
patients and PD patients aged 50–59 years. In all other age
groups, the SMR for HD patients was lower compared with
that of PD patients (Fig. 2).Discussion
In the present study, we examined the mortality rate
among Korean patients on maintenance dialysis therapy in
2009 and 2010 using the HIRA database. In addition, we
calculated the SMR of ESRD patients according to age cate-
gories, sex, and dialysis modality by comparing mortality rates
in the whole population.
The overall prevalence in this study was 1,214.0 PMP in
2009 and 1,268.7 PMP in 2010, which is slightly higher than
that for Korean ESRD patients in a previous report [5], and
lower than reported in epidemiology studies from the United
States (US) renal data system [13]. We originally thought that
the prevalence in this study would be much higher than that
of KSN registry data because the KSN registry program did not
include all Korean dialysis patients. The differences in reported
prevalence may stem from differences in the exclusion criteria.
We excluded patients who survived for fewer than 90 days
from the date of dialysis initiation according to the 90-day rule
of the US renal data system, which is still widely accepted and
has been used in most recent major studies [14,15]. In addi-
tion, we deﬁned the class of dialysis modality as the treatment
modality at the 90th day after commencement of dialysis
without consideration of modality change afterwards, and
thus the numbers of patients on HD or PD were different from
the registry data.
The overall age- and sex-adjusted SMRs in this study were
10.3 and 10.9 in 2009 and 2010, respectively. These rates are
higher than those of the US renal data system, which were
6.5–7.9 [13]. In addition, SMR for cardiovascular and non-
cardiovascular death were reported as 8.8 and 8.1, respectively,
in a European cohort of adults starting dialysis [16]. Further-
more, the SMR for all-cause mortality among Japanese dialysis
Table 2. The standardized mortality ratios according to dialysis modality in 2009 and 2010.
Year Sex
Age group
(y)
Patients on hemodialysis Patients on peritoneal dialysis
N Observed
deaths
Expected
deaths
SMR (95% CI) N Observed
deaths
Expected
deaths
SMR (95% CI)
2009 Male 20–29 467 47 0.3 151.7 (110.7–202.9) 166 19 0.1 172.5 (102.5–271.9)
30–39 1,392 146 1.6 89.2 (75.0–105.2) 547 39 0.6 60.6 (42.8–83.4)
40–49 3,150 349 9.5 36.6 (32.8–40.7) 1,162 101 3.5 28.7 (23.3–35.0)
50–59 5,263 517 33.9 15.3 (13.9–16.7) 1,412 139 9.1 15.3 (12.8–18.1)
60–69 6,060 744 90.7 8.2 (7.6–8.8) 1,221 189 18.3 10.3 (8.9–12.0)
70–79 3,606 588 133.2 4.4 (4.1–4.8) 508 107 18.8 5.7 (4.7–6.9)
Z80 677 137 74.1 1.8 (1.5–2.2) 70 17 7.7 2.2 (1.3–3.6)
subtotal 20,615 2,528 343.0 7.4 (7.1–7.7) 5,086 611 58.1 10.5 (9.7–11.4)
Female 20–29 281 32 0.1 246.2 (166.8–350.0) 131 18 0.1 297.1 (173.5–473.9)
30–39 923 98 0.6 151.2 (122.2–185.0) 471 29 0.3 87.7 (58.2–126.9)
40–49 2,311 288 2.7 105.5 (93.5–118.7) 946 63 1.1 56.4 (43.1–72.5)
50–59 3,809 408 8.4 48.5 (43.8–53.6) 1,128 127 2.5 51.0 (42.3–60.9)
60–69 4,445 656 25.7 25.6 (23.6–27.6) 992 151 5.7 26.4 (22.3–31.0)
70–79 3,233 654 62.2 10.5 (9.7–11.4) 458 100 8.8 11.3 (9.2–13.8)
Z80 668 178 54.2 3.3 (2.8–3.8) 71 18 5.8 3.1 (1.8–5.0)
subtotal 15,670 2,314 154.0 15.0 (14.4–15.7) 4,197 506 24.3 20.8 (19.0–22.8)
Total 36,285 4,842 461.0 9.7 (9.5–10.0) 9,283 1,117 77.1 13.6 (12.8–14.4)
2010 Male 20–29 453 79 0.3 266.9 (210.2–334.0) 170 29 0.1 261.0 (173.1–377.7)
30–39 1,427 223 1.6 138.3 (120.4–158.1) 540 73 0.6 119.6 (93.3–151.1)
40–49 3,199 516 9.4 55.0 (50.3–60.1) 1,158 151 3.4 44.5 (37.5–52.3)
50–59 5,634 675 35.7 18.9 (17.5–20.4) 1,471 213 9.3 22.9 (19.8–26.2)
60–69 6,423 902 93.1 9.7 (9.1–10.4) 1,240 188 18.0 10.5 (9.0–12.1)
70–79 4,209 679 155.8 4.4 (4.0–4.7) 568 102 21.0 4.9 (3.9–5.9)
Z80 837 158 90.7 1.7 (1.5–2.0) 69 19 7.5 2.5 (1.5–4.0)
subtotal 22,182 3,232 386.6 8.4 (8.1–8.7) 5,216 775 59.9 12.9 (12.0–13.9)
Female 20–29 296 46 0.1 378.7 (275.3–508.1) 126 24 0.1 464.2 (294.0–696.3)
30–39 919 138 0.6 231.5 (193.8–274.4) 462 70 0.3 233.6 (181.1–296.5)
40–49 2,282 288 2.7 108.0 (95.6–121.5) 956 111 1.1 99.4 (81.4–120.1)
50–59 3,971 408 8.5 47.8 (43.2–52.8) 1,150 158 2.5 64.0 (54.2–75.0)
60–69 4,616 656 25.9 25.3 (23.4–27.4) 961 190 5.4 35.2 (30.3–40.7)
70–79 3,654 654 68.5 9.6 (8.8–10.3) 478 102 9.0 11.4 (9.2–13.9)
Z80 830 178 67.1 2.7 (2.3–3.1) 71 16 5.7 2.8 (1.6–4.6)
subtotal 16,568 2,368 173.4 13.7 (13.1–14.2) 4,204 671 24.0 27.9 (25.8–30.2)
Total 38,750 5,600 518.0 10.0 (9.7–10.3) 9,420 1,446 78.1 17.2 (16.3–18.2)
CI, conﬁdence interval; SMR, standardized mortality ratio.
Choi et al / Excess mortality in ESRD patients 93patients was 4.6 [17], which was much lower than that of our
study. Life expectancy in the general population differs by
country [18], so the comparison of the mortality rate among
Korean dialysis patients with those of other countries could
provide us with more straightforward information. The mor-
tality rate in Japan was 94.1 per 1,000 person-years in
2008–2009, and that in the US was 284 deaths per 1,000
person-years in 2011 [13,17]. Although we could not calculate
the death rate per 1,000 person-years in this study, the overall
survival rate of Korean dialysis patients in the KSN registry
data was lower than those observed in the US and Japan [5].
The overall SMR in this study, however, seemed to be higher
than those in other countries. The possible reason(s) for the
discrepancy should be explored.
In agreement with the results of a previous report [19], the
SMR decreased as the age of both male and female patients
increased, thus older Korean patients on maintenance dialysis
also had a lower risk for excess mortality. There was, however,
a signiﬁcant difference in the method of calculating the
number of expected deaths between the previous study [19]
and ours. Direct comparison of the respective values may
therefore not be possible.
Although life expectancy is usually longer for females than
for males in the general population, sex has not been considered
to be a risk factor for death in Korean ESRD patients [5]. The SMR
of females calculated in this study, however, was 2.1-fold higher
than that of males, which is similar to a previous report [19]. Asthe survival rate of female patients was not much different from
that of male patients [20], we must recognize that the outcomes
for female patients on dialysis are severely compromised com-
pared with the general population.
Next, we compared the SMR between patients on HD and
PD. In this study, the overall SMR for PD patients was higher
than that for HD patients, which is consistent with a previous
report [19]. However, the SMR for PD patients was lower than
that for HD among patients aged 30–49 years, whereas
opposite results were shown in other age groups. In addition,
throughout all age groups, the SMR of female patients was
higher than that of male patients, regardless of dialysis
modality.
This study has limitations inherent in its study design. First,
we could not gather the cause of death for all individuals.
Second, potential confounding factors for mortality were
unavailable, such as data regarding residual renal function,
critical laboratory results, biomarkers of inﬂammation or
nutrition, and doses of dialysis. Third, we were not able to
get the exact date of death because the clinics only reported
claim data to the HIRA once a month. Finally, the patients
included in this study were those on maintenance dialysis, and
thus we could neither consider the dialysis duration as a
confounding variable for mortality analysis nor evaluate the
sequential changes in the SMR.
In spite of these limitations, our study has provided several
clinically-relevant points. We were able to gather all data of
Figure 2. Gradual changes in the average standardized mortality
ratio (SMR) for the years 2009 and 2010 according to age categories
and dialysis modality. The SMR sequentially decreased with increasing
age category, and the SMR for males was lower than that for females. In
addition, the SMR for peritoneal dialysis (PD) patients was comparable
to or higher than that for hemodialysis (HD) patients, except in patients
aged between 30 years and 49 years.
Kidney Res Clin Pract 33 (2014) 89–9494prevalent Korean patients on dialysis, therefore the results of
this study regarding prevalence, overall SMR, and SMR accord-
ing to age, sex, and dialysis modality could be used for baseline
epidemiologic data for future studies.
Taken together, the present ﬁndings suggest that the SMR
among Korean ESRD patients is likely to be higher than in
other countries. Further studies therefore are needed to
evaluate the reasons for these differences and to improve the
outcomes.Conﬂicts of interest
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